相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment
Daniel A. Tatosian et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Inter-Individual Variability
Hiroyuki Takita et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2021)
Dose-Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs
Daiki Mori et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Simultaneous quantification of coproporphyrin-I and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid in human plasma using ultra-high performance liquid chromatography coupled to tandem mass spectrometry
Yosuke Suzuki et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2020)
Physiologically-Based Pharmacokinetic Modelling of Creatinine-Drug Interactions in the Chronic Kidney Disease Population
Hiroyuki Takita et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2020)
Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug Substrates
Ming-Liang Tan et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers
Daiki Mori et al.
DRUG METABOLISM AND PHARMACOKINETICS (2019)
Effect of Hepatic Organic Anion-Transporting Polypeptide 1B Inhibition and Chronic Kidney Disease on the Pharmacokinetics of a Liver-Targeted Glucokinase Activator: A Model-Based Evaluation
Arthur Bergman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug-Drug Interaction and Associated Biomarker Levels in Healthy Volunteers
Sook Wah Yee et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2019)
Decreased Disposition of Anticancer Drugs Predominantly Eliminated via the Liver in Patients with Renal Failure
Ken-ichi Fujita et al.
CURRENT DRUG METABOLISM (2019)
Uremic solutes modulate hepatic bile acid handling and induce mitochondrial toxicity
Karl M. Weigand et al.
TOXICOLOGY IN VITRO (2019)
Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin I
Shelby Barnett et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
Clinical Pharmacokinetics in Kidney Disease Fundamental Principles
Tom N. Lea-Henry et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug-Drug Interactions
Annett Kunze et al.
CLINICAL PHARMACOKINETICS (2018)
Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives
Flavia Storelli et al.
CLINICAL PHARMACOKINETICS (2018)
Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic Modeling and Simulation
Shelby Barnett et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium
Raymond Evers et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Prediction and Quantification of Hepatic Transporter-Mediated Uptake of Pitavastatin Utilizing a Combination of the Relative Activity Factor Approach and Mechanistic Modeling
Pallabi Mitra et al.
DRUG METABOLISM AND DISPOSITION (2018)
Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP
Ming-Liang Tan et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Combined proportional and additive residual error models in population pharmacokinetic modelling
Johannes H. Proost
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance
J. O. Miners et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Systematic and Quantitative Assessment of the Effect of Chronic Kidney Disease on CYP2D6 and CYP3A4/5
K. Yoshida et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition
Yurong Lai et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
Organ Impairment-Drug-Drug Interaction Database: A Tool for Evaluating the Impact of Renal or Hepatic Impairment and Pharmacologic Inhibition on the Systemic Exposure of Drugs
C. K. Yeung et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2015)
Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin
Thomayant Prueksaritanont et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Reduced Physiologically-Based Pharmacokinetic Model of Repaglinide: Impact of OATP1B1 and CYP2C8 Genotype and Source of In Vitro Data on the Prediction of Drug-Drug Interaction Risk
Michael Gertz et al.
PHARMACEUTICAL RESEARCH (2014)
Quantitative Prediction of Transporter- and Enzyme-Mediated Clinical Drug-Drug Interactions of Organic Anion-Transporting Polypeptide 1B1 Substrates Using a Mechanistic Net-Effect Model
Manthena V. Varma et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin
Yi-an Bi et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2013)
Understanding the Critical Disposition Pathways of Statins to Assess Drug-Drug Interaction Risk During Drug Development: It's Not Just About OATP1B1
R. Elsby et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Comparison of the Safety, Tolerability, and Pharmacokinetic Profile of a Single Oral Dose of Pitavastatin 4 mg in Adult Subjects With Severe Renal Impairment Not on Hemodialysis Versus Healthy Adult Subjects
Roger E. Morgan et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2012)
Evaluation of Exposure Change of Nonrenally Eliminated Drugs in Patients With Chronic Kidney Disease Using Physiologically Based Pharmacokinetic Modeling and Simulation
Ping Zhao et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Applications of minimal physiologically-based pharmacokinetic models
Yanguang Cao et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2012)
Use of Mechanistic Modeling to Assess Interindividual Variability and Interspecies Differences in Active Uptake in Human and Rat Hepatocytes
Karelle Menochet et al.
DRUG METABOLISM AND DISPOSITION (2012)
Modeling and predicting drug pharmacokinetics in patients with renal impairment
Karen Rowland Yeo et al.
Expert Review of Clinical Pharmacology (2011)
Effects of chronic renal failure on liver drug transporters
Judith Naud et al.
DRUG METABOLISM AND DISPOSITION (2008)
Gender differences in mRNA expression of ATP-binding cassette efflux and bile acid transporters in kidney, liver, and intestine of 5/6 nephrectomized rats
Hong Lu et al.
DRUG METABOLISM AND DISPOSITION (2008)
Differential regulation of basolateral and canalicular transporter expression in rat liver in chronic renal failure.
B Holzer et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Association of kidney function with anemia - The Third National Health and Nutrition Examination Survey (1988-1994)
BC Astor et al.
ARCHIVES OF INTERNAL MEDICINE (2002)
Relationship between hematocrit and renal function in men and women
CY Hsu et al.
KIDNEY INTERNATIONAL (2001)
分享论文
